Sept 29 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* NYKODE THERAPEUTICS INITIATES PHASE 1/2A TRIAL OF VB10.16
IN
FIRST LINE HPV16-POSITIVE HEAD AND NECK CANCER
* TRIAL EVALUATES VB10.16, COMPANY'S WHOLLY OWNED OFF--SHELF
THERAPEUTIC CANCER VACCINE CANDIDATE FOR HPV16-POSITIVE CANCERS
* EVALUATES VB10.16 IN COMBINATION WITH MSD'S (MERCK & CO.,
RAHWAY, NJ, USA) PD-1 INHIBITOR KEYTRUDA® (PEMBROLIZUMAB)
* MERCK WILL SUPPLY KEYTRUDA, WHILE NYKODE RETAINS ALL
COMMERCIAL
RIGHTS TO VB10.16 WORLDWIDE
Source text for Eikon: ID:nObiyPGgRa
Further company coverage: NYKD.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))